How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?: Making the right clinical decisions for rare diseases with the right tools

Anne Musters; Sander W. Tas

How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?: Making the right clinical decisions for rare diseases with the right tools

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	591-593
Journal	Rheumatology (Oxford, England)
Volume	57
Issue number	4
Early online date	2017
Publication status	Published - 2018

Cite this

@article{9748c022bf3f41208f34755e1d659e69,

title = "How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?: Making the right clinical decisions for rare diseases with the right tools",

author = "Anne Musters and Tas, {Sander W.}",

year = "2018",

language = "English",

volume = "57",

pages = "591--593",

journal = "Rheumatology (Oxford, England)",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "4",

}

How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?: Making the right clinical decisions for rare diseases with the right tools. / Musters, Anne ; Tas, Sander W.
In: Rheumatology (Oxford, England), Vol. 57, No. 4, 2018, p. 591-593.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?: Making the right clinical decisions for rare diseases with the right tools

AU - Musters, Anne

AU - Tas, Sander W.

PY - 2018

Y1 - 2018

M3 - Article

C2 - 28339729

SN - 1462-0324

VL - 57

SP - 591

EP - 593

JO - Rheumatology (Oxford, England)

JF - Rheumatology (Oxford, England)

IS - 4

ER -